XML 46 R34.htm IDEA: XBRL DOCUMENT v3.25.2
Collaborative Research and Development Agreements - Schedule of Milestone Achieved (Details) - USD ($)
 3 Months Ended 6 Months Ended
Jun. 30, 2025
Dec. 31, 2024
Sep. 30, 2024
Jun. 30, 2024
Dec. 31, 2022
Sep. 30, 2021
Jun. 30, 2021
Mar. 31, 2021
Mar. 31, 2020
Jun. 30, 2019
Sep. 30, 2018
Dec. 31, 2017
Jun. 30, 2017
Jun. 30, 2016
Mar. 31, 2016
Dec. 31, 2015
Jun. 30, 2015
Jun. 30, 2025
Jun. 30, 2024
Oct. 31, 2021
Disaggregation of Revenue [Line Items]                                        
Collaboration revenue $ 22,263,000     $ 10,971,000                           $ 50,034,000 $ 18,150,000  
Milestone revenue recognition                                   Cash is generally received within 30 days of milestone achievement    
GSK | PD-1 (Jemperli/Dostarlimab) | Initiated in vivo toxicology studies using good laboratory practices (GLPs)                                        
Disaggregation of Revenue [Line Items]                                        
Collaboration revenue                                 $ 1,000,000.0      
GSK | PD-1 (Jemperli/Dostarlimab) | IND clearance from the FDA                                        
Disaggregation of Revenue [Line Items]                                        
Collaboration revenue                             $ 4,000,000.0          
GSK | PD-1 (Jemperli/Dostarlimab) | Phase 2 clinical trial initiation                                        
Disaggregation of Revenue [Line Items]                                        
Collaboration revenue                         $ 3,000,000.0              
GSK | PD-1 (Jemperli/Dostarlimab) | Phase 3 clinical trial initiation - first indication                                        
Disaggregation of Revenue [Line Items]                                        
Collaboration revenue                     $ 5,000,000.0                  
GSK | PD-1 (Jemperli/Dostarlimab) | Phase 3 clinical trial initiation - second indication                                        
Disaggregation of Revenue [Line Items]                                        
Collaboration revenue                   $ 5,000,000.0                    
GSK | PD-1 (Jemperli/Dostarlimab) | Filing of the first BLA - first indication                                        
Disaggregation of Revenue [Line Items]                                        
Collaboration revenue                 $ 10,000,000.0                      
GSK | PD-1 (Jemperli/Dostarlimab) | Filing of the first MAA - first indication                                        
Disaggregation of Revenue [Line Items]                                        
Collaboration revenue                 $ 5,000,000.0                      
GSK | PD-1 (Jemperli/Dostarlimab) | Filing of the first BLA - second indication                                        
Disaggregation of Revenue [Line Items]                                        
Collaboration revenue               $ 10,000,000.0                        
GSK | PD-1 (Jemperli/Dostarlimab) | First BLA approval - first indication                                        
Disaggregation of Revenue [Line Items]                                        
Collaboration revenue             $ 20,000,000.0                          
GSK | PD-1 (Jemperli/Dostarlimab) | First MAA approval - first indication                                        
Disaggregation of Revenue [Line Items]                                        
Collaboration revenue             $ 10,000,000.0                          
GSK | PD-1 (Jemperli/Dostarlimab) | First BLA approval - second indication                                        
Disaggregation of Revenue [Line Items]                                        
Collaboration revenue           $ 20,000,000.0                            
GSK | PD-1 (Jemperli/Dostarlimab) | Filing of the first MAA - second indication                                        
Disaggregation of Revenue [Line Items]                                        
Milestones that may be recognized in the future                                   $ 5,000,000.0    
GSK | PD-1 (Jemperli/Dostarlimab) | First MAA approval - second indication                                        
Disaggregation of Revenue [Line Items]                                        
Milestones that may be recognized in the future                                   10,000,000.0    
GSK | PD-1 (Jemperli/Dostarlimab) | First commercial sales milestone                                        
Disaggregation of Revenue [Line Items]                                        
Collaboration revenue     $ 15,000,000.0                                  
GSK | PD-1 (Jemperli/Dostarlimab) | Second commercial sales milestone                                        
Disaggregation of Revenue [Line Items]                                        
Collaboration revenue   $ 25,000,000.0                                    
GSK | PD-1 (Jemperli/Dostarlimab) | Third commercial sales milestone                                        
Disaggregation of Revenue [Line Items]                                        
Milestones that may be recognized in the future                                   50,000,000.0    
GSK | PD-1 (Jemperli/Dostarlimab) | Fourth commercial sales milestone                                        
Disaggregation of Revenue [Line Items]                                        
Milestones that may be recognized in the future                                   75,000,000.0    
GSK | PD-1 (Jemperli/Dostarlimab) | Milestones recognized through June 30, 2025                                        
Disaggregation of Revenue [Line Items]                                        
Collaboration revenue                                   133,000,000.0    
GSK | PD-1 (Jemperli/Dostarlimab) | Milestones that may be recognized in the future                                        
Disaggregation of Revenue [Line Items]                                        
Milestones that may be recognized in the future                                   140,000,000.0    
GSK | TIM-3 (GSK4069889/Cobolimab) | Initiated in vivo toxicology studies using good laboratory practices (GLPs)                                        
Disaggregation of Revenue [Line Items]                                        
Collaboration revenue                               $ 1,000,000.0        
GSK | TIM-3 (GSK4069889/Cobolimab) | IND clearance from the FDA                                        
Disaggregation of Revenue [Line Items]                                        
Collaboration revenue                           $ 4,000,000.0            
GSK | TIM-3 (GSK4069889/Cobolimab) | Phase 2 clinical trial initiation                                        
Disaggregation of Revenue [Line Items]                                        
Collaboration revenue                       $ 3,000,000.0                
GSK | TIM-3 (GSK4069889/Cobolimab) | Phase 3 clinical trial initiation - first indication                                        
Disaggregation of Revenue [Line Items]                                        
Collaboration revenue         $ 5,000,000.0                              
GSK | TIM-3 (GSK4069889/Cobolimab) | Phase 3 clinical trial initiation - second indication                                        
Disaggregation of Revenue [Line Items]                                        
Milestones that may be recognized in the future                                   5,000,000.0    
GSK | TIM-3 (GSK4069889/Cobolimab) | Filing of the first BLA - first indication                                        
Disaggregation of Revenue [Line Items]                                        
Milestones that may be recognized in the future                                   10,000,000.0    
GSK | TIM-3 (GSK4069889/Cobolimab) | Filing of the first MAA - first indication                                        
Disaggregation of Revenue [Line Items]                                        
Milestones that may be recognized in the future                                   5,000,000.0    
GSK | TIM-3 (GSK4069889/Cobolimab) | Filing of the first BLA - second indication                                        
Disaggregation of Revenue [Line Items]                                        
Milestones that may be recognized in the future                                   10,000,000.0    
GSK | TIM-3 (GSK4069889/Cobolimab) | First BLA approval - first indication                                        
Disaggregation of Revenue [Line Items]                                        
Milestones that may be recognized in the future                                   20,000,000.0    
GSK | TIM-3 (GSK4069889/Cobolimab) | First MAA approval - first indication                                        
Disaggregation of Revenue [Line Items]                                        
Milestones that may be recognized in the future                                   10,000,000.0    
GSK | TIM-3 (GSK4069889/Cobolimab) | First BLA approval - second indication                                        
Disaggregation of Revenue [Line Items]                                        
Milestones that may be recognized in the future                                   20,000,000.0    
GSK | TIM-3 (GSK4069889/Cobolimab) | Filing of the first MAA - second indication                                        
Disaggregation of Revenue [Line Items]                                        
Milestones that may be recognized in the future                                   5,000,000.0    
GSK | TIM-3 (GSK4069889/Cobolimab) | First MAA approval - second indication                                        
Disaggregation of Revenue [Line Items]                                        
Milestones that may be recognized in the future                                   10,000,000.0    
GSK | TIM-3 (GSK4069889/Cobolimab) | First commercial sales milestone                                        
Disaggregation of Revenue [Line Items]                                        
Milestones that may be recognized in the future                                   15,000,000.0    
GSK | TIM-3 (GSK4069889/Cobolimab) | Second commercial sales milestone                                        
Disaggregation of Revenue [Line Items]                                        
Milestones that may be recognized in the future                                   25,000,000.0    
GSK | TIM-3 (GSK4069889/Cobolimab) | Third commercial sales milestone                                        
Disaggregation of Revenue [Line Items]                                        
Milestones that may be recognized in the future                                   50,000,000.0    
GSK | TIM-3 (GSK4069889/Cobolimab) | Fourth commercial sales milestone                                        
Disaggregation of Revenue [Line Items]                                        
Milestones that may be recognized in the future                                   75,000,000.0    
GSK | TIM-3 (GSK4069889/Cobolimab) | Milestones recognized through June 30, 2025                                        
Disaggregation of Revenue [Line Items]                                        
Collaboration revenue                                   13,000,000.0    
GSK | TIM-3 (GSK4069889/Cobolimab) | Milestones that may be recognized in the future                                        
Disaggregation of Revenue [Line Items]                                        
Milestones that may be recognized in the future                                   260,000,000.0    
Sagard | JEMPERLI Royalty Monetization Agreement                                        
Disaggregation of Revenue [Line Items]                                        
Rights retained                                       $ 75,000,000
Royalties agreement, maximum annual royalty payout capacity                                       $ 1,000,000,000
Vanda | Milestones recognized through June 30, 2025                                        
Disaggregation of Revenue [Line Items]                                        
Collaboration revenue                                   0    
Milestones that may be recognized in the future                                   35,000,000.0    
Vanda | FDA regulatory approval for marketing of first licensed product in the USA for the treatment of active flares in GPP                                        
Disaggregation of Revenue [Line Items]                                        
Milestones that may be recognized in the future                                   5,000,000.0    
Vanda | Regulatory approval for marketing of the first licensed product in the EU                                        
Disaggregation of Revenue [Line Items]                                        
Milestones that may be recognized in the future                                   5,000,000.0    
Vanda | Commercial sales first exceed $100.0 million                                        
Disaggregation of Revenue [Line Items]                                        
Milestones that may be recognized in the future                                   25,000,000.0    
Commercial sales                                   $ 100,000,000.0